Article | January 12, 2023

Quality Assured: Bringing Life-Changing Therapies To Patients

By Rob Frater, Laboratory Manager, and Arthur Stevenson, QP Services Manager, Qualified Person, PCI Pharma Services

Quality Management GettyImages-1336716297

CDMOs play an essential role in the pharmaceutical industry, supporting companies to deliver products to patients swiftly and efficiently. PCI’s flexibility and agility ensures we are well positioned to assist with any number of challenges that may arise. Biopharmaceutical drug development remains a key trend, demanding specific expertise and capabilities when it comes to Quality Assurance.

As a CDMO, we must provide consistency in approach, reliability in service, flexibility in meeting the varied nature of requirements, and true expertise in the areas contracted to us. A strong focus on identifying any issues and pursuing corrective and preventive action (CAPA) in a timely manner is also of core importance.

In this article, we explore four areas in biologics that appear to be major talking points for our customers, which means they’re also of fundamental importance to PCI.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader